Boston Scientific Receives FDA Approval For Promus Premier(TM) Everolimus …Wall Street JournalNATICK, Mass., Nov. 25, 2013 /PRNewswire/ — Continuing to advance leading drug-eluting stent (DES) technology, Boston Scientific Corporation (NYSE: BSX) ha…
Medscape |
Tacrolimus a Prospect for Connective Tissue Lung Disease
Medscape Tacrolimus is a calcineurin inhibitor with multiple immunomodulatory mechanisms. Its use in patients with connective tissue–related lung disease has not yet been investigated. However, controlled trials have shown that it is an effective treatment for … |
Combination Therapy For Severe Alcoholic Hepatitis Does Not Result in …Toronto NewsFIXFour weeks of treatment with a combination of the drug pentoxifylline and the corticosteroid prednisolone did not improve 6-month survival compared with prednisolon…
|
Merck’s New Drug Application for an Investigational Intravenous (IV …
MarketWatch Concomitant administration of NOXAFIL with cyclosporine or tacrolimus increases the whole blood trough concentrations of these calcineurin inhibitors. Nephrotoxicity and leukoencephalopathy (including isolated deaths) have been reported in clinical … |
OncLiveSubgroup Analyses Show Depth of Everolimus Benefit in BOLERO-2OncLiveNew analyses of the BOLERO-2 trial found that everolimus and exemestane produced significantly longer progression-free survival (PFS) than placebo and exemestane in several pre…
OncLiveEverolimus Offers Benefit in Papillary Renal Cell CarcinomaOncLiveEverolimus provides clinical benefit to patients with papillary metastatic renal cell carcinoma (RCC), offering promising overall survival (OS) results and a tolerable side-effect…
Oral sirolimus with BMS may reduce in-stent restenosisHealioA short-term regimen of oral sirolimus after bare-metal stent implantation yielded significant reductions of in-stent restenosis and target lesion revascularization, according to recent findin…
Stentys Updates on Sirolimus-Eluting Stent StudyHispanicBusiness.comStentys , a medical technology company commercializing in Europe the Self-Apposing Stent to treat acute myocardial infarction, announced results from the four-month arm of the Appositi…
Drug Discovery & Development |
Pfizer Inc. : Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of …
4-traders (press release) Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE® (sirolimus) evaluating kidney transplant patients who transitioned from tacrolimus-based therapy (TAC) to RAPAMUNE® 3 to 5 months after transplant. The primary … Pfizer Inc. (NYSE:PFE) | Pfizer Announces Top-Line Results Of Phase 3B/4 …Jutia Group Pfizer says organ transplant drug fails in studyBusinessweek Pfizer’s Rapamune Doesn’t Meet Primary Endpoint in Study of Kidney Transplant …Wall Street Journal |
Pfizer Announces Top-Line Results Of Phase 3B/4 Study Of RAPAMUNE(R …MarketWatchNEW YORK, Nov 08, 2013 (BUSINESS WIRE) — Pfizer Inc. (NYSE:PFE) announced today top-line results from a Phase 3B/4 study of RAPAMUNE(R) (sirolimus) evaluating kidney tra…